1 Patriot Place
About Homology Medicines
Homology Medicines is based on groundbreaking science that harnesses the naturally occurring process of homologous recombination. This non-nuclease-based approach offers clear advantages in its precision, efficiency and on-target in vivo editing of genetic mutations. Homology obtained an exclusive worldwide license to this technology platform, which is based on the pioneering research of Saswati Chatterjee, Ph.D., Professor of Virology at the Beckman Research Institute at the City of Hope in California, member of the Recombinant DNA Advisory Committee (RAC) to the Office of the Director, National Institutes of Health (NIH) and former charter member of the Therapeutic Approaches to Genetic Diseases Study Section of the NIH. Dr. Chatterjee and her team led the first adeno-associated virus (AAV) vector-mediated gene transfer studies into human hematopoietic stem cells and subsequently identified and isolated a series of naturally-occurring AAVs from human CD34+ cells.
Founder: Saswati Chatterjee
President and CEO: Arthur Tzianabos, Ph.D.
CSO: Albert Seymour, Ph.D.
Please click here for Homology job opportunities.
29 articles with Homology Medicines
Mr. Patterson is a biotech industry leader with more than 24 years of experience in research, development and commercialization of innovative treatments for rare diseases.
Homology Medicines and Novartis Enter Collaboration to Develop New Treatments Using Homology's Proprietary Gene Editing Technology
Under the terms of the agreement, Novartis made an upfront payment to and an equity investment in Homology.
Homology Medicines Strengthens Manufacturing And Product Development Expertise With Appointment Of Tim Kelly As Senior Vice President, Technical Operations
Homology Medicines Presents Data Demonstrating Highly Efficient, On-Target In Vivo Gene Editing Capabilities Of Its Novel Human-Derived Adeno-Associated Virus Vectors
BioSpace is proud to present its NextGen “Class of 2017,” which is a list of 20 up-and-coming life science companies that launched no earlier than 2014.
Homology Medicines Acquires License To Novel AAV Technology To Develop Treatments For Central Nervous System Disorders